Olodaterol monotherapy set for Phase III testing in COPD
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has completed the Phase II programme of olodaterol monotherapy in patients with chronic obstructive pulmonary disease (COPD) and has "set the stage" for the drug to be tested as a monotherapy in Phase III.